Guanglin received his B.S. degree in Chemistry from Fudan University and his M.S. degree from the Shanghai Institute of Organic Chemistry. Guanglin then pursued his doctorate with Prof David Cane at Brown University where he conducted research on the biosynthesis of macrocyclic polyketides. He carried out his postdoctoral studies at Harvard in the laboratory of Prof E. J. Corey where he applied the polyene cyclization strategy to the asymmetric synthesis of two natural products. Guanglin subsequently joined BMS where he is now a Scientific Director. Guanglin was the primary inventor for BMS-927711/rimegepant, a CGRP antagonist for migraine, for which he presented a first time disclosure in March of 2012. Rimegepant was recently approved by the FDA for both acute and preventive treatment of migraine as Nurtec ODT at Biohaven Pharmaceuticals.